Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21)

The summary for the Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21): This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of a cancer-relevant intended use and requires significant modification for the proposed application. The emphasis of this FOA is on molecular analysis technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, prevention, diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.
Federal Grant Title: Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-13-001
Type of Funding: Grant
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: Sep 20, 2013
Original Application Deadline: Sep 20, 2013
Posted Date: Nov 09, 2012
Creation Date: Nov 09, 2012
Archive Date: Oct 21, 2013
Total Program Funding: $5,000,000
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards: 25
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com